Develops and markets men's wellness products. Offers erectile dysfunction treatments under the Mango brand. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
This company is not turning a profit, so the market is pricing its sales instead: 14.3× for every dollar of annual revenue.
Against companies in its own sector, it looks cheaper than 19% of them.
No analyst target is on record for this company.
Executives buying with their own money is usually read as confidence in the company’s future.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Growth: Sales growth trails the sector average.
Business Quality: Profit power and business quality trail similar companies in the sector.
An investor who bought at the very peak is down 99% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $456K a year. A small number, but proof the product has real buyers.
Over the last 12 months, company executives reported 5 buys and 4 sells. Management buying with its own money is usually read as a good sign.
A loss of $20.6M against $456K in annual sales. And on top of that, sales fell from the year before.
The stock sits at $0.39. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
This stock swings about 2.1 times as much as the market average. Big rallies — and big drops — can both happen fast.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: earnings execution, the revenue breakdown.